,i #aagth ,,congress #ast ,session ,h4 ,r4 #adgc ,,in ,,the ,,house ,,of ,,representatives ,march #a1 #bjba,mr4 ,steube introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to require the ,commissioner of ,food and ,drugs and the ,director of the ,centers for ,disease ,control and ,prevention to report to ,congress all serious adverse events that are reported to such agencies in connection with administration of a ,,covid-#ai vaccine1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,vaccine ,transparency ,act of #bjba4 #b4 ,reports to ,congress on serious adverse events in connection with ,,covid-#ai vaccines 7a7 ,in general ,not later than #fj days after the date of enactment of this ,act1 and every #fj days thereafter1 the ,commissioner of ,food and ,drugs and the ,director of the ,centers for ,disease ,control and ,prevention1 acting jointly1 shall submit a report to the ,congress on all serious adverse events that are reported-- 7#a7 to either agency pursuant to the ,vaccine ,adverse ,event ,reporting ,system or otherwise during the period covered by the report2 and 7#b7 in connection with a ,,covid-#ai vaccine4 7b7 ,initial report ,the reporting period of the initial report under subsection 7a7 shall begin on the date when the ,commissioner of ,food and ,drugs first authorized emergency use of a ,,covid-#ai vaccine under section #efd of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb-#c74